SD BIOSENSOR
Global in-vitro diagnostics and biosensor manufacturing company.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
* | N/A | Acquisition | |
| Total Funding | 000k | ||
| KRW | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | - | (78 %) | 6 % | 8 % | 10 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 50 % | 44 % | (23 %) | 19 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 37 % | 31 % | (71 %) | (14 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1 % | 2 % | 10 % | 13 % | - | - |
Source: Company filings or news article, Equity research estimates
SD BIOSENSOR, Inc. is a South Korean in-vitro diagnostics (IVD) company that develops, manufactures, and supplies diagnostic solutions globally. The company was founded in 2010 by Chairman Young-Sik Cho, a researcher in the diagnostics field since 1984. After establishing and later selling a previous diagnostics company named SD to Alere Inc., Cho spun off SD BIOSENSOR to focus initially on blood glucose monitoring systems.
The company gained significant international recognition for developing rapid diagnostic tests, particularly its STANDARD Q COVID-19 antigen test. Before the pandemic, a large portion of its revenue came from blood glucose monitors. SD BIOSENSOR's product portfolio is extensive, categorized under brand names such as STANDARD Q (rapid immunochromatography tests), STANDARD F (fluorescent immunoassay), STANDARD E (ELISA tests), and STANDARD M (point-of-care molecular diagnostics). Their offerings cover a wide range of applications, including tests for respiratory, blood-borne, and vector-borne diseases. A key product is the STANDARD M10, a point-of-care molecular diagnostics system that provides real-time PCR results for infectious diseases, drug resistance, and genetic testing.
SD BIOSENSOR operates on a global scale, serving healthcare providers and laboratories with point-of-care testing (POCT) solutions. Its business model involves the research, development, and sale of these diagnostic products and platforms, including rapid tests, immunoassay analyzers, and molecular diagnostic systems. The company went public with an initial public offering on the KOSPI board in July 2021, raising approximately $680 million to expand production and its global presence. Headquartered in Suwon, South Korea, the company has established international subsidiaries in countries including the USA, India, Germany, and Brazil to support its worldwide distribution network.
Keywords: in-vitro diagnostics, point-of-care testing, rapid diagnostic tests, biosensors, molecular diagnostics, immunodiagnostics, blood glucose monitoring, STANDARD Q, STANDARD M10, immunoassay, ELISA, Young-Sik Cho, KOSPI, diagnostic reagents, antigen test, healthcare diagnostics, IVD, POCT, infectious disease testing, confirmatory tests
